A study of Smad4, Smad6 and Smad7 in Surgically Resected Samples of Pancreatic Ductal Adenocarcinoma and Their Correlation with Clinicopathological Parameters and Patient Survival
<p>Abstract</p> <p>Background</p> <p>Smad4 is the common mediator of the tumor suppressive functions of TGF-beta. Smad6 and Smad7 are the antagonists of the TGF-beta pathway. This study investigates the differential protein expressions of Smad4, Smad6 and Smad7 in tumor...
Main Authors: | Singh Puneet, Srinivasan Radhika, Wig Jai, Radotra Bishan |
---|---|
Format: | Article |
Language: | English |
Published: |
BMC
2011-12-01
|
Series: | BMC Research Notes |
Subjects: | |
Online Access: | http://www.biomedcentral.com/1756-0500/4/560 |
Similar Items
-
SMAD4 and the TGFβ Pathway in Patients with Pancreatic Ductal Adenocarcinoma
by: Julie Dardare, et al.
Published: (2020-05-01) -
Integration of Bioinformatics Resources Reveals the Therapeutic Benefits of Gemcitabine and Cell Cycle Intervention in SMAD4-Deleted Pancreatic Ductal Adenocarcinoma
by: Yao-Yu Hsieh, et al.
Published: (2019-09-01) -
Role of TGF-β/Smad Signaling Pathway-Related Proteins in Clinicopathological Features and Prognosis and Survival of Patients with Nasopharyngeal Carcinoma
by: Yanwei Rao, et al.
Published: (2021-03-01) -
Non-Canonical Functions of SMAD2 and SMAD3 During Myogenic Differentiation and Fusion
by: Lamarche, Emilie
Published: (2018) -
Differential Role of Smad2 and Smad3 in the Acquisition of an Endovascular Trophoblast-Like Phenotype and Preeclampsia
by: Jelena Brkić, et al.
Published: (2020-07-01)